Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for December 2008
December 1, 2008
- Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
- Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers
- TorreyPines' NGX426 Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
- Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
- Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
- Tracking Eye Disorders in Statin Users; Predicting Visual Outcomes for Wounded Soldiers; Improving Glaucoma Tests with Patient Input
- Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis
- Study: Patient Harm More Common with Patient-Controlled Pain Medication
- Experimental TB Drug Explodes Bacteria From The Inside Out
December 2, 2008
- TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
- Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
- GSK and Theravance Announce Positive Phase 2b Results for LABA, '444 in the Horizon Asthma Development Programme
- Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference
- First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical's Electroporation Technology Shows Safety and Durable Systemic Clinical Response
- XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease
- Inovio: final melanoma trial results confirm systemic effect and safety
- Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
- TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
- Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
- Gemin X Announces Data Presentations for its Novel, Targeted Cancer Therapy Obatoclax at the 50th Annual American Society of Hematology Meeting and Exposition
- GENFIT Therapeutic Potential of GFT505 is Demonstrated in the Treatment of Cardiovascular Risk Associated With Pre-Diabetes
- SuperGen to Present Data at the 50th ASH Annual Meeting & Exposition
December 3, 2008
- OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
- PN 400 Phase III Studies Show Clinically Meaningful Benefit in Reducing Gastric Ulcers Compared to Enteric-Coated Naproxen
- POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 Trials
- Generex Announces Positive Results of Metformin Chewing Gum Trial
- Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows
- Celgene Corporation and Acceleron Pharma to Present ACE-011 Data at the 50th Annual Meeting of the American Society of Hematology
- Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
- Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
- Results of Studies of Eslicarbazepine Acetate for the Treatment of Epilepsy to Be Presented at American Epilepsy Society Annual Meeting
- Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
- Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
- Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 ASH Annual Meeting
- Nymox Reports Positive New Clinical Trial Data on Improvement in Urinary Urgency and Frequency Symptoms in Patients on NX-1207 Drug for Prostate Enlargement
- Surprising Results on Smoking Research Hispanic Versus White Female Smokers
December 4, 2008
- ConjuChem's PC-DAC:Exendin-4 Lowers Glucose and Weight in Phase II Diabetes Trials
- Data Demonstrating Significant Efficacy of Viread in Treating Chronic Hepatitis B Published in New England Journal of Medicine
- EpiCept Reports New Data on Benefits of Maintenance Therapy With Ceplene and interleukin-2 For AML Patients At ASH Annual Meeting
- More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
- Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference
- Data on Stapled Peptide Drugs to Be Presented at ASH Annual Meeting
- Zevalin Data to be Presented at ASH 2008
- EpiCept Reports New Data on Benefits of Maintenance Therapy With Ceplene and interleukin-2 For AML Patients At ASH Annual Meeting
- MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
- Starpharma Holdings Limited SPL7013 Shows Activity Against All Major Clinically Relevant Human Papillomavirus (HPV) Strains
- Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
- Inovio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DNA Vaccines at International DNA Vaccines Conference
- Novelos Therapeutics and Academic Collaborators Present Posters at 2008 AACR Tumor Immunology Conference
- Archemix Announces ARC1779 Data to Be Presented at Upcoming American Society of Hematology (ASH) Annual Meeting, December 6-9, 2008
- Results From the First and Largest Collaborative Study Confirm Role of Enbrel in Psoriatic Arthritis
- Kiadis Pharma Announces Positive Clinical Results for ATIR in Mismatched Bone Marrow Transplantations - Kiadis Pharma Proceeds with Pivotal Trial ATIR
December 5, 2008
- ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom 0.09%
- Novel Basis Identified for Tamoxifen Failure
- New Data Suggest Cimzia Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease
- BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
- Data on Stapled Peptide Drugs to Be Presented at ASH Annual Meeting
- GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
- New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management
- Hepatitis C Treatment Reduces the Virus but Liver Damage Continues
- Vandalia Research to Present DNA Manufacturing Technology at Two Major Vaccine Conferences during December
December 8, 2008
- GlycoMimetics, Inc. to Present New Results of Lead Candidate in Additional Animal Models of Sickle Cell Disease at American Society of Hematology Annual Meeting
- Human Genome Sciences Announces Albuferon Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
- Presentation on Cytopia's JAK2 Inhibitor Program in Myeloproliferative Disorders
- Human Genome Sciences to Sponsor Conference Call - Dec 8, 2008
- Avila Presents Data on Novel Btk Inhibitor, AVL-101, for B Cell Malignancies
- Exelixis Reports Phase 1 Data for XL019 at ASH Annual Meeting
- ZIOPHARM Presents Positive Darinaparsin Phase II Data at ASH Meeting
- Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
- Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy
- Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits in Myelofibrosis Patients
- GPC Biotech Announces Presentation of New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor at the American Society of Hematology Annual Meeting
- Sosei Confirms the Safety of SD118 in Two Phase I Trials
- Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
- Phase III Trial Results Show Elitek (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
- Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures
- Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma Trial
- Allos Therapeutics Announces Top Line Results from Pivotal Phase 2 PROPEL Trial of Pralatrexate in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
- Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
- Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
- Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology
- Ligand Presents Positive LGD-4665 Clinical Trial Results at theAmerican Society of Hematology Annual Meeting
- Dynavax Presents Preclinical Data Supporting Its Novel Universal Flu Vaccine Candidate
- New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
- Rivaroxaban Reduces Symptomatic VTE & Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of the RECORD Clinical Trial Program
- Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
- Novel Velcade (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
- Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
- Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
- Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
- Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
- SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia
- Vion Pharmaceuticals Presents Additional Survival Data on Onrigin (Laromustine) Injection at ASH Annual Meeting
- Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
- Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
- Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine
- Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix
- Zevalin Consolidation in First-Line Therapy in Patients with Non-Hodgkin's Lymphoma Resulted in a Progression-Free Survival of Greater Than 67 Months
- Gloucester Pharmaceuticals Announces Positive Results from Romidepsin T-cell Lymphoma Clinical Trials at ASH
- Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
- Encore Therapeutics Inc. Demonstrates Proof of Concept for a Long-acting Buprenorphine Depot for Pain and Drug Abuse Therapy (ETI-311)
- Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
- Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
- Exelixis Reports Positive Phase 1 Data for XL228 at ASH Annual Meeting
- ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate in Drug-Resistant CML Patients with the T315I Mutation
- Multiple Vimpat (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
- Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug Trial in Patients with Multiple Myeloma
- Sciele Pharma and Plethora Solutions Announce Final Analysis of PSD502 for Premature Ejaculation; All Primary and Secondary Endpoints Met in Phase III Pivotal Trial
- Long-term Follow Up Interim Data Show Nplate Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
- Xarelto Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program
- First Head-to-Head Study Shows that Protelos (Strontium Ranelate) Builds Better Bone Than Bisphosphonate
- Antisoma Announces Positive Interim Data from AS1411 Phase II Trial in Acute Myeloid Leukaemia
- Data Presented At ASH Illustrates that Continued Treatment with Vidaza Can Benefit MDS Patients
December 9, 2008
- Twenty New Abstracts on Oral Xeloda (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium
- Soliris Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension
- SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
- Micromet Presents Updated Data on the Phase 1 Trial Studying Blinatumomab (MT103/MEDI-538) in Patients with Advanced Non-Hodgkin's Lymphoma
- Arzerra (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
- ASH Presentation Shows Continued Treatment with Vidaza Improves Responses in Patients with Higher-Risk Myelodysplastic Syndromes
- Prolonged Progression-Free Survival Demonstrated by Velcade (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
- Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
- Continued Overall Survival Advantage Reported From Pivotal Trial of Velcade (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
- AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
- New Keppra XR Data Highlight Its Role for Patients with Partial-Onset Seizures
- Video: Tasigna Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
- Dyloject Significantly Reduces Moderate-to-Severe Pain in Pivotal Phase 3 Orthopedic Surgical Trial
- ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Inhibition of All Known Variants of the CML Target Protein Bcr-Abl
- Exjade Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial
- Genzyme Reports Clolar Data Further Supporting Potential of Product to Treat Adult AML Patients
- Dacogen (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)
- Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath in Patients with High-Risk CLL
- ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings Reported at ASH Annual Meeting
- ZymoGenetics Presents Favorable Recothrom Phase 3b Results
- AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs in Treating Post-Operative Pain
- PolyMedix to Present At HIV DART 2008 on Novel Antimicrobial Compounds for Treatment of Drug Resistant Tuberculosis
- Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
- Updated Data Evaluating Clinical Benefit of Revlimid Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma Presented At ASH
- Study Presented at the American Society of Hematology Reports Revlimid Activity in Patients with Relapsed/Refractory Mantle-Cell Lymphoma
- Futura Medical Announces Positive Phase I Results for PET500
- Arzerra (Ofatumumab) Demonstrates High Response Rates in Patients with Fludarabine Refractory Chronic Lymphocytic Leukaemia (CLL)
- Targacept Announces Conference Call to be held Today at 5:30 p.m. and Updates Guidance
- Second-Generation CML Drugs Show Promise as Frontline Therapy
- Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
- Zolinza (vorinostat) in Combination with Bortezomib Showed Clinical Response in Early Investigational Studies of Patients with Relapsed or Refractory Multiple Myeloma
- ASH Presentation Highlights Durable Responses with Antisoma's AS1413 in Secondary AML
- Medivation Presents New Data on Dimebon's Novel Mechanism of Action
- Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
- Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
- Celator Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
- Synergy Pharmaceuticals Successfully Completes Phase I Trial of SP-304 in Volunteers
- Gemin X Presents New Data on Obatoclax at the American Society of Hematology Meeting
- Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia
- Velcade (bortezomib) Findings Reinforce Efficacy and Survival Across Multiple Patient Populations
- Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
- Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels
- Intense Chemotherapy Wards off Recurrence in Half of Mantle Cell Lymphoma Patients after Seven Years
- Updated Revlimid Data in Newly-Diagnosed Multiple Myeloma Reports Unprecedented Three-Year Survival Rates in Phase III ECOG E4A03 Study
- M. D. Anderson News Release: New Therapy Prevents Dangerous Side Effect for Lymphoma Patients
- New Data Demonstrate Activity, Combinability of Novel Cancer Therapy Obatoclax - Results Presented at ASH 2008
December 10, 2008
- Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization
- Alexza's AZ-004 (Staccato Loxapine) Meets Primary Endpoint of Treating
- Diabetes Drug Shows Potential For Treating One Cause Of Chronic Kidney Disease
- Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate
- Consumer Health Sciences Presents Important Data On the Unmet Needs of Depression Patients At the ISPOR 11th Annual European Congress
- Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
- CAL-101, an Oral p110? Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Preclinical Activity in Hematologic Cancer Cells
- Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
- PolyMedix Announces Positive Phase I Clinical Data with PMX-30063 Novel Antibiotic Drug Candidate
- Study Showed New Episodes of Depression Delayed in People Taking Cymbalta
- Sarah Cannon Research Institute to Present New Trial Results at San Antonio Breast Cancer Symposium
- MabThera Maintenance Therapy Helps Non-Hodgkin’s Lymphoma Patients Live for Years Longer Without Their Disease Progressing
- ERYtech Pharma Announces the Results of Its Phase II Clinical Trial
- Active Biotech's Cancer Project Anyara: Combination with Established Tumor Therapies Promising
- Promising Results from Two Trials Highlighting Developmental Oral IMiDS Compound Pomalidomide Presented at the American Society of Hematology Meeting
- GlaxoSmithKline to Present New Tykerb/Tyverb (Lapatinib) Data at SABCS 2008
- New Data Evaluating Abraxane in Early-Stage Breast Cancer and in Combination with Novel Investigational Agents to Be Presented at SABCS
December 11, 2008
- Qnexa Meets Primary Endpoint by Demonstrating Superior Weight Loss over Components and Placebo in the 28-Week Equate Study (OB-301)
- Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
- Data from Eight Clinical Trials Facilitated by the Multiple Myeloma Research Consortium (MMRC) Presented at the American Society of Hematology (ASH) Annual Meeting
- InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
- Oncolytics Biotech Inc.'s Reolysin Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
- Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
- Femara First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
- PolyMedix Announces Positive Phase I Clinical Data
- Oncolytics Biotech Inc.'s Reolysin Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
- CST New Data Show Zometa Enhances Impact of Chemotherapy on Reducing Breast Tumor Size
- Combination of Tykerb (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
- Pfizer Announces Results from Trial of Aromasin in Postmenopausal Women with Hormone Sensitive Early Breast Cancer
December 12, 2008
- Qnexa Reduces Hemoglobin A1c By 1.6% in 56 Weeks
- SARcode Announces Completion of Phase 1 Clinical Trial of SAR 1118 Ophthalmic Solution
- New Data from Largest-Ever Clinical Trials in CLL Show Rituxan (Rituximab) Enables Leukemia Patients to Live Longer Without Their Disease Progressing
- Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
- Gleevec Leads to Longest Survival Reported for Patients with Life-threatening Form of Leukemia, 7-year IRIS Data Show
- Lexicon's Drug Candidate LX6171 for Cognitive Disorders Completes Phase 2A Clinical Trial
- K-State Researcher Finds Correlation Between Childhood Obesity and Asthma
- Ablynx Reports Positive Phase Ib Results for its Anti-Thrombotic Nanobody ALX-0081
- First Phase III Results for FTY720, a Novel Oral Therapy for MS, Show Superior Efficacy Compared to Interferon Beta-1a
- Novelos Therapeutics Announces Presentation of Positive Results in Ongoing Phase 2 Neoadjuvant Breast Cancer Trial at San Antonio Breast Cancer Symposium
- Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer
December 15, 2008
- RAD001 Shows Potential to Reverse Resistance to Herceptin in Metastatic Breast Cancer Patients, Leading to Phase III Trial
- Theratechnologies Reports 52-week Confirmatory Phase 3 Results
- Study Finds Doxil Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
- Positive Phase II Study of Pacira's Exparel (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
- Theratechnologies Reports 52-week Results in its Confirmatory Phase 3 Trial with Tesamorelin
- Abraxane in Combination with Gemcitabine and Epirubicin Evaluated as Neoadjuvant Treatment for Patients with Locally Advanced Breast Cancer
- Alexion Reports Positive Results From Aegis Registration Study Of Soliris In Japanese Patients With PNH
- Study Finds Doxil Combination Therapy Delays Disease Progression for Patients with Metastatic Breast Cancer
December 16, 2008
- Antisoma plc (UK) - Phase II trial showing improved survival with ASA404 in lung cancer published in British Journal of Cancer
- MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
- QLT announces interim results of radical study evaluating Visudyne combination therapy
- US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
- Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on Xerecept Clinical Program and Planned Sale in 2009
- Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
- Nymox Releases New Study Data from U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Which Shows Significantly Less Interruption of Sleep For Men Given Nymox Drug
December 17, 2008
- NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis
- Starpharma Holdings Ltd (ASX:SPL) Dendrimer Reduces Toxicity of Cancer Drug
- Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID
- Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
- Lead Drug In Phase 3 Trial Has Potential To Be First FDA-Approved Prescription Topical NSAID Cream Product
- Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer's Compound Anavex 1-41 Published in Journal of Neuropsychopharmacology
December 18, 2008
- MannKind Reports Top-Line Results from Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
- CrystalGenomics Announces Positive Phase IIa Results for Osteoarthritis Study of CG100649
- New Analysis of Discovery Labs' Phase 3 RDS Trials Identifies Reintubation as Key Risk Factor for Infant Mortality
- ARYx Therapeutics, Inc. Announces Successful Outcome of Atrial Fibrillation Clinical Trial on ATI-2042
- ACE-011 Phase 1 Results Published in the Journal of Bone and Mineral Research
- Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis
- Arete Therapeutics Reports Positive Phase I Data for AR9281
- Common Treatment for Chronic Prostatitis Fails to Reduce Symptoms
December 19, 2008
- NicOx' Naproxcinod Shows Differentiated 24-Hour Blood Pressure Profile After 13 Weeks Treatment
- Phase III Study Showed Rituxan Decreased the Progression of Joint Damage in Patients with Early Rheumatoid Arthritis (RA)
- Arpida Publishes Top-Line Data of Phase II "Intravenous-To-Oral" Switch Trial With Oral Iclaprim
- Memory Pharmaceuticals Reports Phase 1 Data for R4996/MEM 63908
- Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times
- Biofrontera AG (DE) - Ad hoc: Biofrontera AG: Excellent Phase III-results with BF-200 ALA
- MabThera inhibits the destruction of joints in patients with early rheumatoid arthritis
December 22, 2008
- BioCryst Pharmaceuticals Continues Forodesine HCl Program in Chronic Lymphocytic Leukemia
- RegeneRx Updates Schedule for Release of Clinical Trial Information
- Pre-clinical Research on EVATAK in Human Gastric (Stomach) Cancer Accepted for Publication
- GSK and Theravance Announce Positive Phase 2b Results for LABA '444 in the Treatment of COPD in the Horizon Development Programme
December 23, 2008
- ImmunoCellular Therapeutics' Cancer Vaccine Demonstrates Immune Response Against Brain Cancer in Clinical Trial
- Molecular Insight's Zemiva Demonstrates Ability to Improve Early Diagnosis of the Chest Pain Patient in the Emergency Department
- NicOx Announces Results for TPI 1020 in COPD
- Dionysos Study Results Showed The Respective Profiles of Dronedarone and Amiodarone
- ImQuest Presentations at International HIV Meeting Highlight Significant Progress in Their Therapeutic and Microbicide Development Programs
- Napo Pharmaceuticals Announces Publication of Paper on Crofelemer for Indication of Irritable Bowel Syndrome
- Northwest Biotherapeutics Reports Encouraging Data on First Patients Who Have Completed Its Phase I/II Clinical Trial of DCVax-L in Metastatic Ovarian Cancer
